Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

41. Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes. (PubMed)

Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes. Prices for newer analogue insulin products have increased. Lower-cost human insulin may be effective for many patients with type 2 diabetes.To evaluate the association between implementation of a health plan-based intervention of switching patients from analogue to human insulin and glycemic control.A retrospective cohort study using (...) population-level interrupted times series analysis of members participating in a Medicare Advantage and prescription drug plan operating in 4 US states. Participants were prescribed insulin between January 1, 2014, and December 31, 2016 (median follow-up, 729 days). The intervention began in February 2015 and was expanded to the entire health plan system by June 2015.Implementation of a health plan program to switch patients from analogue to human insulin.The primary outcome was the change in mean

2019 JAMA

42. Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes

Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes Discover Portal Discover Portal Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes Published on 11 July 2017 doi: People with type 1 diabetes offered insulin pumps did not achieve better blood glucose control compared with those using multiple daily injections (...) . Education remains important. While both groups saw improvements in blood glucose levels and fewer hypoglycaemic episodes (very low blood sugar) over two years, only one in four participants met NICE blood glucose targets. Insulin pump users showed some modest improvements in satisfaction, dietary freedom and daily hassle. All participants in this NIHR trial attended a training course on managing their insulin levels before randomisation. This is important because previously observed benefits from pump

2019 NIHR Dissemination Centre

43. Continuous insulin pumps may help manage poorly controlled type 2 diabetes

Continuous insulin pumps may help manage poorly controlled type 2 diabetes Continuous insulin pumps may help manage poorly controlled type 2 diabetes Discover Portal Discover Portal Continuous insulin pumps may help manage poorly controlled type 2 diabetes Published on 18 July 2017 doi: Continuous subcutaneous insulin infusions, or pumps, reduced the amount of daily insulin required by 24 units for people with advanced type 2 diabetes compared to multiple daily insulin injections. Average (...) weight did not differ between treatments. This review compared the two treatments in 590 people from five trials and found that the pumps were linked to slightly better control for people on higher doses of insulin and those with poorer glucose control. However, looking at all the people with diabetes in these studies, there was no difference in overall control between the different forms of treatment. One main challenge in controlling type 2 diabetes is the low adherence to treatment. Other studies

2019 NIHR Dissemination Centre

44. Insulin pumps offer little value over multiple injections for children at the onset of diabetes

Insulin pumps offer little value over multiple injections for children at the onset of diabetes Insulin pumps or multiple injections for children at onset of diabetes Discover Portal Discover Portal Insulin pumps offer little value over multiple injections for children at the onset of diabetes Published on 20 November 2018 doi: Young people newly diagnosed with type 1 diabetes achieve similar blood glucose control by 12 months if they are treated with multiple daily insulin injections (...) or continuously via an insulin pump. Adverse events are rare and occur at similar rates. Pumps are more expensive with no clear benefit to quality of life. Both regimens are used in the management of type 1 diabetes, and the number of children using insulin pumps is rising. This NIHR-funded trial suggests that at an additional cost of £1,863 per patient annually with equivalent outcomes, the high costs of insulin pumps seem unjustified at this stage of the condition. However, continuous insulin may be more

2019 NIHR Dissemination Centre

45. Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3

Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3 Basal insulin therapy often involves a compromise between achievement of glycaemic targets and avoidance of hypoglycaemia, dependent on how intensively insulin is titrated. In the Phase 3a EDITION 1, 2 and 3 studies, insulin glargine 300 U/mL (Gla-300) provided glycaemic control equivalent to that of insulin glargine 100 U/mL (Gla-100), with less

Full Text available with Trip Pro

2019 EvidenceUpdates

46. Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia

Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia Maintaining optimal glycaemic control reduces the risk of micro- and macrovascular complications in patients with type 2 diabetes. Typically, glycaemic control is based on glycated haemoglobin (HbA1c) as a measure of mean glucose concentration; however, this marker does not accurately reflect glycaemic variability (GV), which is characterized by the amplitude (...) , frequency and duration of hypo- and hyperglycaemic fluctuations. In the present study, we analysed data from the LixiLan-O trial, which compared iGlarLixi, a titratable fixed-ratio combination of the glucagon-like peptide-1 receptor agonist lixisenatide (Lixi) and long-acting basal insulin glargine 100 units/mL (iGlar), with its individual components, and the LixiLan-L trial, which compared iGlarLixi with iGlar. The GV features that were measured were mean and SD of self-measured plasma glucose (SMPG

Full Text available with Trip Pro

2019 EvidenceUpdates

47. The efficacy and safety of pioglitazone vs insulin treatment in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials

The efficacy and safety of pioglitazone vs insulin treatment in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

48. The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with non-alcoholic fatty liver disease: a systematic review

The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with non-alcoholic fatty liver disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

49. Relationship between acne vulgaris and insulin resistance markers and effect of isotretinoin on insulin resistance markers in patients with acne vulgaris: a systematic review and meta-analysis

Relationship between acne vulgaris and insulin resistance markers and effect of isotretinoin on insulin resistance markers in patients with acne vulgaris: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

50. Effect of Paleo diet on glucose and insulin homeostasis

Effect of Paleo diet on glucose and insulin homeostasis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

51. Comparative efficacy and safety of metformin, glyburide and insulin in treating gestational diabetes mellitus: a meta-analysis

Comparative efficacy and safety of metformin, glyburide and insulin in treating gestational diabetes mellitus: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

52. Dietary inflammatory index, blood pressure, fasting blood sugar and biomarkers of insulin resistance among adults: a systematic review and meta-analysis

Dietary inflammatory index, blood pressure, fasting blood sugar and biomarkers of insulin resistance among adults: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

53. Dietary antioxidant capacity (TAC), general and central obesity indices, blood pressure, fasting blood sugar, biomarkers of insulin resistance and inflammation among adults

Dietary antioxidant capacity (TAC), general and central obesity indices, blood pressure, fasting blood sugar, biomarkers of insulin resistance and inflammation among adults Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

54. Dietary acid load, blood pressure, fasting blood sugar and biomarkers of insulin resistance among adults: findings from an updated systematic review and meta-analysis

Dietary acid load, blood pressure, fasting blood sugar and biomarkers of insulin resistance among adults: findings from an updated systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

55. A systematic and meta-analysis of the chain of insulin, C-peptide and glucose levels with improvement in cognition in the elderly with physical activity

A systematic and meta-analysis of the chain of insulin, C-peptide and glucose levels with improvement in cognition in the elderly with physical activity Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

56. Efficacy of inulin supplementation on insulin metabolism in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Efficacy of inulin supplementation on insulin metabolism in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

57. HLA-DQB1 polymorphisms in insulin-dependent diabetes mellitus (IDDM) children developing coeliac disease: a meta-analysis

HLA-DQB1 polymorphisms in insulin-dependent diabetes mellitus (IDDM) children developing coeliac disease: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

58. Is evening carbohydrate intake associated with poor glucose tolerance and reduced insulin sensitivity when compared with day intake? A systematic review

Is evening carbohydrate intake associated with poor glucose tolerance and reduced insulin sensitivity when compared with day intake? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

59. Insulin-like growth factor-1 for the prevention or treatment of retinopathy of prematurity [Cochrane protocol]

Insulin-like growth factor-1 for the prevention or treatment of retinopathy of prematurity [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

60. Insulin versus Oral Therapies for Gestational Diabetes Treatment: Meta-analysis and Network Meta-analysis

Insulin versus Oral Therapies for Gestational Diabetes Treatment: Meta-analysis and Network Meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO